CROI 2020 Abstract eBook

Abstract eBook

Poster Abstracts

treatment has to be individualized, and not given on the basis of this cancer type only. Other gene alterations were present in the rest of the patients, that could thus become a possible target for check-point inhibitors or for other anti-tumor drugs, such as mTOR or tyrosine kinase inhibitors, even if these drugs are not registered or studied in these specific cancers. During the follow-up, however, none of the patients received any of these potentially active drugs. Conclusion: FoundationOne CDx could give relevant information on treatment strategies in subjects with cancer and HIV infection, so becoming an important tool in personalized medicine. Indeed, the study of genomic signatures and gene alterations could indicate also in HIV+ patients with cancer (and not only on the basis of tumor type) the possible use of check-point inhibitors or eventually of other anticancer drugs that are registered for that specific cancer or for other cancer types.

Wallis, Mann–Whitney, and Spearman's rank tests were used for statistical analyses. False discovery rates (FDR) were calculated to account for multiple comparisons. Results: Levels of the anti-inflammatory galactosylated glycans were lower in the IgG of HIV+ cases compared to HIV+ controls (FDR=0.005; Fig. 1A). Consistently, levels of the pro-premature-aging agalactosylated glycans were higher in HIV+ cases compared to HIV+ controls (FDR<0.02). These differences were not observed between HIV- cases and HIV- controls. We also found that levels of the pro-inflammatory hypo-sialylated and agalactosylated glycans were higher in the plasma of HIV+ cases compared to HIV- cases (FDR<0.01; Fig. 1B). Examining the links between galactosylation and risk/degree of cardiovascular disease (CVD), we found that levels of several IgG and plasma galactosylated glycans associated with lower CVD scores, including FRS, segment stenosis, and plaque severity; whereas levels of agalactosylated glycans associated with higher scores (FDR<0.05; Fig. 1C). Conclusion: Premature-aging-associated glycomic dysregulation, in particular, agalactosylation and hyposialyation, are more evident among HIV+ ART+ individuals (compared to all other groups) and are associated with the prevalence and degree of subclinical atherosclerosis. Potential HIV-promoted glycomic pathways fostering CVD warrant further investigation to examine their prognostic and functional significance.

Poster Abstracts

635 HOST GLYCOMIC DETERMINANTS OF CORONARY ATHEROSCLEROSIS DURING TREATED HIV INFECTION Leila B. Giron 1 , Susan Langan 2 , David B. Hanna 3 , Juan Lin 3 , Mohammad Damra 1 , Qin Liu 1 , Ian Frank 4 , Mallory Witt 5 , Lawrence Kingsley 6 , Frank J. Palella 7 , Wendy Post 2 , Alan Landay 8 , Todd T. Brown 2 , Mohamed Abdel-Mohsen 1 1 Wistar Institute, Philadelphia, PA, USA, 2 Johns Hopkins University, Baltimore, MD, USA, 3 Albert Einstein College of Medicine, Bronx, NY, USA, 4 University of Pennsylvania, Philadelphia, PA, USA, 5 Los Angeles Biomedical Research Institute at Harbor–UCLA Medical Center, Torrance, CA, USA, 6 University of Pittsburgh, Pittsburgh, PA, USA, 7 Northwestern University, Chicago, IL, USA, 8 Rush University, Chicago, IL, USA Background: HIV-induced inflammation is associated with accelerated atherosclerosis, even after virally suppressive antiretroviral therapy (ART). In the general population, host glycomic alterations, in particular, loss of galactose and sialic acid on circulating glycoproteins (including IgG) drive inflammation and are associated with premature aging. Whether glycomic alterations contribute to the development of coronary atherosclerosis during HIV infection remains unknown. Methods: We designed a case-control study within the Multicenter AIDS Cohort Study (MACS); cases had coronary stenosis ≥50% in one or more coronary segments and controls had no coronary plaque (by CT angiography). We used a 1:1 nearest neighbor matching algorithm to select 34 HIV+ ART+men cases / 34 HIV+ ART+ controls, and 22 HIV- men cases / 22 HIV- controls. Median Framingham Risk Score (FRS) was similar between HIV+ cases and controls (7 vs 6, p=0.8), but different between HIV- cases and controls (11 vs 7, p=0.01). Capillary electrophoresis was used to profile plasma and IgG glycomes. Kruskal-

636 ADVANCED GLYCATION END PRODUCTS ASSOCIATED WITH CARDIOMETABOLIC RISK ON ART

Vanessa El Kamari 1 , Katherine Rodriguez 2 , Carlee Moser 2 , Judith S. Currier 3 , Theodoros Kelesidis 3 , James H. Stein 4 , Scott K. Howell 5 , Paul J.Beisswenger 5 , Todd T.Brown 6 , Grace A.McComsey 1 1 University Hospitals Cleveland Medical Center, Cleveland, OH, USA, 2 Harvard T.H. Chan School of Public Health, Boston, MA, USA, 3 University of California Los Angeles, Los Angeles, CA, USA, 4 University of Wisconsin–Madison, Madison, WI,

CROI 2020 230